Introduction
PAPA syndrome (Pyogenic Arthritis, Pyoderma gangrenosum, and Acne) is an ultra-rare autosomal dominant, autoinflammatory disease associated to mutations in the PSTPIP1/CD2BP1 gene. The therapeutic approach during recurrences consists of steroids, while no agreement exists on the chronic management. Evidences on the use of biologics are anecdotal and variable results have been reported.
Objectives
To evaluate the long-term response to treatment with IL1 antagonist in six patients affected by PAPA syndrome.
Methods
Six patients (M:F=3:3; 4 pediatric, 1 young adult and 1 adult, mean age 18 years, range 3-50) affected by PAPA syndrome were enrolled and treated with IL1 blockers (5 patients Anakinra, 1 patient Anakinra followed by Canakinumab). Three patients were already treated with anti-TNFα monoclonal antibodies without benefit. Data were collected retrospectively (mean follow-up 26 months, range 4-38). The frequency of articular and cutaneous flares in the 24 months before starting therapy where compared to those occurred during anti-IL1 regimen. Acute phase reactants (ESR, CRP, 1 IRCCS G. Gaslini, U.O. Pediatria II, Genoa, Italy Full list of author information is available at the end of the article Finetti et al. Pediatric Rheumatology 2015, 13(Suppl 1):P207 http://www.ped-rheum.com/content/13/S1/P207
